Aug. 26, 2022

BI-4142: A HER2 exon 20 Insertion Mutant Inhibitor for NSCLC

BI-4142

oral HER2 exon 20 mutants selective inhibitor tumor regression in the HER2YVMA xenograft model from 12k compounds in-house library screening and opt Nat. Cancer, July 26, 2022 Boehringer Ingelheim RCV, Vienna, AT

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in